4/19
06:34 am
ifrx
Global Sepsis Therapeutics Strategic Research Report 2024: Market to Reach $7.1 Billion by 2030 - Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth [Yahoo! Finance]
Medium
Report
Global Sepsis Therapeutics Strategic Research Report 2024: Market to Reach $7.1 Billion by 2030 - Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth [Yahoo! Finance]
3/22
08:22 am
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/21
10:35 am
ifrx
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
3/21
07:17 am
ifrx
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans [Yahoo! Finance]
Neutral
Report
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans [Yahoo! Finance]
3/21
07:00 am
ifrx
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
Medium
Report
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
3/19
07:30 am
ifrx
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
High
Report
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
2/22
07:44 am
ifrx
InflaRx Appoints Jan Medina as Head of Investor Relations [Yahoo! Finance]
Medium
Report
InflaRx Appoints Jan Medina as Head of Investor Relations [Yahoo! Finance]
2/22
07:30 am
ifrx
InflaRx Appoints Jan Medina as Head of Investor Relations
Medium
Report
InflaRx Appoints Jan Medina as Head of Investor Relations
1/25
11:25 am
ifrx
InflaRx (NASDAQ: IFRX) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
InflaRx (NASDAQ: IFRX) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
1/25
07:41 am
ifrx
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients [Yahoo! Finance]
Medium
Report
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients [Yahoo! Finance]
1/25
07:30 am
ifrx
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
Medium
Report
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
1/25
05:48 am
ifrx
InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions [Yahoo! Finance]
Medium
Report
InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions [Yahoo! Finance]